MAP2K7 and melanoma: Since now the standard of care for V600EBRAF mutated melanoma patients is combination treatment with BRAF and MEK inhibitors, we are conducting a re-structured phase I/II study using decitabine in combination with vemurafenib and cobimetinib where we are exploring the effect of low dose decitabine for a longer duration.